COVID-19 Vaccine

• CMAVirtual Grand Rounds: COVID-19 in Pregnancy and Birth 5-11-21 12-1:30 p.m. PST Register
• CDC Vaccine Training Modules (with CE) – new Janssen module. Modules include a general overview of immunization practices, and Janssen, Pfizer and Moderna vaccine storage, handling, preparation, administration, and documentation. Modules
• COVID-19 Vaccine Training: What Every Clinician Needs to Know: NEJM Knowledge+ is launching this COVID-19 Vaccine Training, a free CME course that covers the fundamentals of the COVID-19 vaccines and the practicalities of how they are used. Available through June 30^th, 2021. Learn more
• CDC/IDSA COVID-19 Clinician Calls Weekly Series - Saturdays at noon PST. Register for Webinars

View recorded webinars

DPH Resources

• Vaccine information for the public webpage: includes FAQs, vaccine myths, and vaccine scams. Patients can also sign up to receive email newsletters with vaccine updates. Materials are available in multiple languages.
• After you get a vaccine webpage: includes topics such as common side effects, allergic reactions, what you can do after you are fully vaccinated, and vaccination records.

CDC Resources - Answering patients’ questions about COVID-19 vaccine:

• Engaging in Effective Vaccine Conversations webpage
• Tips and sample scripts of how to answer likely questions webpage
• Common Questions People May Ask Healthcare Professionals 2 page handout
• Patient FAQs

FDA Resources

• Vaccine EUA fact sheets for recipients and caregivers Pfizer Moderna Janssen

• CDC/IDSA COVID-19 Clinician Call: The Johnson & Johnson Vaccine: Current Situation & Anticipated Next Steps 4-17-21 Recording will be posted at http://www.idsociety.org/cliniciancalls
• CDC COCA webinar on cerebral venous sinus thrombosis (CVST) with thrombocytopenia associated J&J vaccine - including updated vaccine recommendations 4-15-21. Slides Recording
• CDC/IDSA COVID-19 Clinician Call: : COVID-19 in Pregnant Individuals; Plus Vaccine Q&A - Hosted in Partnership with ACOG. 4-10-21 Recording, slides, and Q&A transcript
• COVID-19 Conversations: Variants and Vaccines. American Public Health Association/National Academy of Medicine webinar recorded on 3-17-21. Webinar available 3-18-21 at www.covid19conversations.org
• The Role of Telehealth in Expanding Access to Healthcare During the COVID-19 Pandemic: Considerations for Vaccine Uptake and Monitoring for Adverse Events: CDC COCA webinar recorded on 3-11-21 at 11 am PST. Free CME available. View webinar
• What Every Clinician Should Know about COVID-19 Vaccine Safety and Effectiveness and How to Address Patient Questions and Concerns: CDC COCA webinar recorded on 3-9-21 at 11 am PST. Webcast
• CHHS & CMA Virtual Grand Rounds: Fighting to the Finish - COVID-19 Vaccines vs Variants recorded on 3-9-21. Webcast Slides
• CDC COCA Call: What Clinicians Need to Know About the Janssen COVID-19 Vaccine3-2-21 Slide Set Recording
• CDC Advisory Committee on Immunization Practices (ACIP) meeting 3-1-21 Slides Webcast 
• Strategies for Turning a Corner on COVID-19-Vaccine Rollout, Virus Variants, and Vaccine Hesitance Recorded 2-9-21 Virtual Grand Rounds hosted by the California Health and Human Services Agency (CHHS) and the California Medical Association (CMA). Recording, Slides
• CDC COCA Call: COVID-19 Vaccines: Update on Allergic Reactions, Contraindications, and Precautions 12-30-20 Slides Recording
• CDC COCA Call: What Clinicians Need to Know About the Pfizer-BioNTech and Moderna COVID-19 Vaccines 12-18-20  Slides Recording
• ASCO/IDSA Webinar: The COVID-19 Vaccine & Patients with Cancer  12-17-20 Recording

Vaccine Administration Provider Line -Questions about vaccine distribution, storage and handling, and guidance on registering to receive the vaccine through the CDPH enrollment website.

• Monday through Friday, 8:00am- 5:00pm call 833-505-0761 or email COVIDVaccineReq@ph.lacounty.gov.

Vaccine Clinical Provider Line –Clinical questions about COVID-19 vaccines including but not limited to contraindications, precautions, side effects, post vaccination assessment

• Monday through Friday, 8:00am-5:00pm, call 213-240-7941. For time-sensitive questions after hours, call 213-974-1234 and ask for the on-call clinician

CDC/CISAvax (Clinical Immunization Safety Assessment Project) - Consults about COVID-19 vaccine safety. Healthcare providers can request a consultation from CISA COVIDvax for a complex COVID-19 vaccine safety question that is (1) about an individual patient residing in the United States or vaccine safety issue and (2) not readily addressed by CDC or Advisory Committee on Immunization Practices (ACIP) guidelines. CISA has vaccine safety subject matter experts in multiple specialties (e.g. ID, allergy/immunology, neurology, OB/GYN, pediatrics, geriatrics)

• Contact CDC_INFO: 800-CDC-INFO (800-232-4636) or online
• In case of an emergent clinical COVID-19 vaccine safety inquiry, healthcare providers can call the CDC Emergency Operations Center (EOC) Watch Desk at (770)-488-7100. The EOC Watch Desk will route emergency inquiries to the CISA COVIDvax on-call staff.

Medical professionals interested in supporting the COVID-19 response:

• Paid positions - contact the California COVID Health Corps
• Volunteer opportunities (including Medical Disaster Service Workers) - contact the City of Los Angeles

Vaccine trial data, press releases, and information from the FDA are below:

Pfizer-BioNTech

• Walsh et al. Safety and immunogenicity of two RNA-Based COVID-19 vaccine candidates. NEJM 2020; online publication Oct 14.
• Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints Press Release 11-18-20
• Phase 3 trial information 12-10-20 New England Journal of Medicine Safety and Efficacy of the BNT162b2 Covid-19 Vaccine  Editorial  Video summary
• Pfizer vaccine: CDC webpage  FDA webpage (includes fact sheets for Healthcare Providers and  Recipients and Caregivers in 20 languages)
• Pfizer vaccine efficacy at 6 months. Pfizer reported the vaccine to be highly effective against symptomatic cases up to 6 months after the second dose, and 100% effective in preventing COVID-19 cases in South Africa, where the B.1.351 lineage is prevalent. Press release 4-1-21
• Pfizer vaccine efficacy in 12-15 year-olds The study demonstrated 100% efficacy in 12-15 year-olds. The company plans to submit an EUA application. 3-31-21 Press release

Moderna

• Jackson et al. An mRNA Vaccine against SARS-CoV-2-Preliminary report. NEJM 2020;20:1920-1931.
• Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate Press Release 11-30-20
• Moderna vaccine: CDC webpage  FDA webpage (includes fact sheets for Healthcare Providers and  Recipients and Caregivers in multiple languages)

Janssen (Johnson & Johnson)

• Janssen COVID-19 Vaccine FDA webpage includes fact sheets (for healthcare providers and for patients and caregivers), FAQs, letter of authorization and decision memo
• Janssen COVID-19 Vaccine (Johnson & Johnson) CDC Product Information webpage
• ACIP Meeting (Feb 28-March 1, 2021) Slides Webcast
• FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting 2-26-21 Agenda and Materials, FDA Briefing Document,  Janssen Briefing Document and Addendum
• Press Releases: Interim Analysis of Phase 3 Clinical Data 1-29-21 See press releases from Johnson & Johnson and the NIH.
• ACIP J&J vaccine meeting - decision to extend pause in vaccine administration 4-14-21. Slides
• Emergency ACIP meeting to discuss J&J vaccine 4-23-21 8am-2pm Meeting information